The transcriptional coactivator SYT (synovial translocation protein) contains a conserved amino terminal SNH domain and a carboxy terminal QPGY domain, which is a functioning transcriptional activating sequence. Synovial sarcoma translocation (SSX) proteins, including SSX1–5, are transcriptional repressors that contain a repressor domain in their carboxy termini. SSX proteins are localized to the nucleus and expressed in testis and several types of cancers and, therefore, they are classified as C/T (cancer/testis) antigens. The t(x;18) translocation results in the fusion of the amino terminus of SYT to the carboxy terminus of either SSX1 or SSX2; both fusions result in the production of transcriptional activators. SYT-SSX chimeras are detected in most synovial sarcomas. Synovial sarcomas are responsible for up to 10% of soft issue sarcomas and are histologically characterized as either biphasic or mono-phasic. Genetic analysis indicates that biphasic synovial sarcomas contain SYT-SSX1 fusions, whereas SYT-SSX2 fusions are found in monophasic synovial sarcomas, providing additional distinguishing characterization of these subtypes.
Key Feature
Clonality
Polyclonal
Isotype
IgG
Host Species
Rabbit
Tested Applications
WBIPIFELISAGSChIP
recommended for detection of SYT and SYT homolog-1 of mouse, rat and human origin by WB, IP, IF and ELISA
Species Reactivity
HumanMouseRat
Concentration
1mg/ml
Purification
Affinity purified
Target Information
Alternative Names
epitope corresponding to amino acids 1-80 mapping at the N-terminus of SYT of human origin
Tissue Specificity
epitope corresponding to amino acids 1-80 mapping at the N-terminus of SYT of human origin